# M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

> **NCT03631706** · PHASE3 · COMPLETED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 304 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** M7824
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03631706
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-01
- **Primary completion:** 2021-06-07
- **Final completion:** 2024-06-25
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2025-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03631706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03631706, "M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03631706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*